Similarly, in colorectal cancer, POLD1-mutant tumors demonstrate enhanced responsiveness to ICIs, with an overall response rate of 89% compared to 54% in dMMR/MSI-H tumors (P=0.01), suggesting that PD-L1-mediated immune suppression is a critical evasion strategy that can be targeted therapeutically (31). This evidence concerns the gene POLD1 and colorectal cancer.